Giuseppe Lucisano
Overview
Explore the profile of Giuseppe Lucisano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
2034
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Iaffaldano P, Portaccio E, Lucisano G, Simone M, Manni A, Guerra T, et al.
JAMA Neurol
. 2023 Nov;
81(1):50-58.
PMID: 38010712
Importance: Although up to 20% of patients with multiple sclerosis (MS) experience onset before 18 years of age, it has been suggested that people with pediatric-onset MS (POMS) are protected...
12.
DErasmo L, Di Martino M, Neufeld T, Fraum T, Kang C, Burks K, et al.
Circulation
. 2023 Sep;
148(19):1479-1489.
PMID: 37712257
Background: ANGPTL3 (angiopoietin-like 3) is a therapeutic target for reducing plasma levels of triglycerides and low-density lipoprotein cholesterol. A recent trial with vupanorsen, an antisense oligonucleotide targeting hepatic production of...
13.
Ceriello A, Lucisano G, Prattichizzo F, La Grotta R, Frige C, De Cosmo S, et al.
Lancet Reg Health Eur
. 2023 Aug;
31:100666.
PMID: 37547276
Background: A delay in reaching HbA1c targets in patients with newly-diagnosed type 2 diabetes (T2D) is associated with an increased long-term risk of developing cardiovascular diseases (CVD), a phenomenon referred...
14.
Giandalia A, Russo G, Ruggeri P, Giancaterini A, Brun E, Cristofaro M, et al.
J Clin Endocrinol Metab
. 2023 May;
108(11):e1224-e1235.
PMID: 37247381
Objective: Obesity is a growing emergency in type 1 diabetes (T1D). Sex differences in obesity prevalence and its clinical consequences in adult T1D subjects have been poorly investigated. The aim...
15.
Ceriello A, Lucisano G, Prattichizzo F, La Grotta R, Franzen S, Gudbjornsdottir S, et al.
Eur J Prev Cardiol
. 2023 Mar;
30(8):719-727.
PMID: 36897149
Aims: Cardiovascular risk factor control fluctuates, tends to change over time, and is potentially impacted by multifactorial interactions. Currently, the presence of risk factors, rather than their variability or interplay...
16.
Simone M, De Giacomo A, Palumbi R, Palazzo C, Lucisano G, Pompamea F, et al.
Int J Mol Sci
. 2023 Feb;
24(3).
PMID: 36769380
Autism spectrum disorder (ASD) is one of the most common neurodevelopment disorders, characterized by a multifactorial etiology based on the interaction of genetic and environmental factors. Recent evidence supports the...
17.
Russo G, Andreozzi F, Calabrese M, Bartolo P, Di Cianni G, Bruno Giorda C, et al.
Diabetes Res Clin Pract
. 2022 Nov;
194:110158.
PMID: 36400169
Aims: Telemedicine is advocated as a fundamental tool in modern clinical management. However, data on the effects of telemedicine vs face-to-face consultation on clinical outcomes in type 2 diabetes (T2DM)...
18.
Iaffaldano P, Lucisano G, Guerra T, Patti F, Onofrj M, Morra V, et al.
Mult Scler
. 2022 Aug;
28(14):2243-2252.
PMID: 35971322
Background: Definitions for reliable identification of transition from relapsing-remitting multiple sclerosis (MS) to secondary progressive (SP)MS in clinical cohorts are not available. Objectives: To compare diagnostic performances of two different...
19.
Portaccio E, Fonderico M, Iaffaldano P, Pasto L, Razzolini L, Bellinvia A, et al.
JAMA Neurol
. 2022 Jul;
79(9):869-878.
PMID: 35877104
Importance: Except for ocrelizumab, treatment options in primary progressive multiple sclerosis (PPMS) are lacking. Objective: To investigate the effectiveness of DMTs on the risk of becoming wheelchair dependent in a...
20.
Ceriello A, Lucisano G, Prattichizzo F, La Grotta R, Franzen S, Svensson A, et al.
Cardiovasc Diabetol
. 2022 Jan;
21(1):13.
PMID: 35073913
Background: HbA1c variability has emerged as risk factor for cardiovascular diseases in diabetes. However, the impact of HbA1c variability on cardiovascular diseases in subjects within the recommended HbA1c target has...